Ventyx Biosciences, Inc.
VTYXDelisted Mar 4, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001851194
Ventyx Biosciences, Inc. was delisted on Mar 4, 2026; its insiders filed their last Form 4 on Mar 4, 2026; 139 institutions reported holding it in 13F filings for Q4 2025, worth $471.6M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:45 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 14, 2025 | Feb 27, 2024 | Mar 23, 2023 | Mar 23, 2022 |
| Operating expenses | $148.4M | $208.0M | $113.1M | $67.1M |
| Research and development | $117.0M | $175.8M | $87.7M | $58.5M |
| Selling, general and administrative | $31.4M | $32.2M | $25.4M | $8.67M |
| Operating income | -$148.4M | -$208.0M | -$113.1M | -$67.1M |
| Net income | -$135.1M | -$193.0M | -$108.4M | -$83.7M |
| EPS, basic | $-1.97 | $-3.30 | $-2.07 | – |
| EPS, diluted | $-1.97 | $-3.30 | $-2.07 | – |
| Weighted shares, basic | 68.5M | 58.5M | 52.5M | – |
| Weighted shares, diluted | 68.5M | 58.5M | 52.5M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 14, 2025 | Feb 27, 2024 | Mar 23, 2023 | Mar 23, 2022 |
| Cash and equivalents | $27.3M | $51.6M | $64.8M | $70.8M |
| Short-term investments | $190.1M | $200.6M | $253.1M | $187.8M |
| Total current assets | $229.6M | $264.3M | $330.7M | $263.0M |
| Property, plant and equipment | $614.0K | $762.0K | $407.0K | $254.0K |
| Total assets | $276.6M | $277.7M | $371.4M | $291.5M |
| Accounts payable | $3.13M | $5.76M | $6.43M | $4.66M |
| Total current liabilities | $12.8M | $22.3M | $16.4M | $12.3M |
| Total liabilities | $22.5M | $33.8M | $17.5M | $12.3M |
| Shareholders' equity | $254.0M | $243.9M | $353.9M | $279.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 14, 2025 | Feb 27, 2024 | Mar 23, 2023 | Mar 23, 2022 |
| Operating cash flow | -$130.9M | -$166.5M | -$98.8M | -$38.6M |
| Capital expenditures | $241.0K | $514.0K | $275.0K | $262.0K |
| Free cash flow | -$131.1M | -$167.0M | -$99.0M | -$38.9M |
| Stock-based compensation | $22.9M | $28.6M | $16.6M | $2.73M |
| Investing cash flow | -$15.5M | $100.9M | -$74.9M | -$214.4M |
| Financing cash flow | $122.1M | $53.3M | $167.8M | $323.6M |
| Net change in cash | -$24.3M | -$12.3M | -$5.97M | $70.5M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2025 | 71.4M | +0.9% | SEC |
| Aug 4, 2025 | 71.3M | +0.9% | SEC |
| May 5, 2025 | 71.2M | +0.9% | SEC |
| Feb 24, 2025 | 71.1M | +20.0% | SEC |
| Nov 4, 2024 | 70.7M | +19.8% | SEC |
| Aug 5, 2024 | 70.7M | +20.0% | SEC |
| May 6, 2024 | 70.5M | +20.4% | SEC |
| Feb 22, 2024 | 59.3M | +1.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.